References
Asch RH, Weckstein LN, Ralmaceda JP, Rojas F, Spitz JM, et al. Non-surgical expulsion of non-viable early pregnancy: a new application of RU 486. Human Reproduction 5: 481–483, 1990
Aubeny E, Baulieu EE. Contragestive activity of RU 486 and oral active prostaglandin combination. Comptes Rendus de L’Academie des Science 312: 539–45, 1991
Birth Control Trust. The Abortion Pill: Widening the choice for women. The Birth Control Trust, London, 1990
Brogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmcodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 44, in press, 1992
Cabrol D, Dubois C, Cronje H, Gonnet JM, Guillot M, et al. Induction of labor with mifepristone (RU 486) in intrauterine fetal death. American Journal of Obstetrics and Gynaecology 163: 540–542, 1990
Castadot RG. Pregnancy termination: techniques, risks, and complications and their management. Fertility and Sterility 45: 5–17, 1986
Cook RJ. Antiprogestin drugs: medical and legal issues. Family Planning Perspectives 21: 267–272, 1989
Couzinet B, le Strat N, Silvestre L, Schaison G. Late luteal administration of the antiprogesterone RU 486 in normal women: effects on the menstrual cycle events and fertility control in a long-term study. Fertility and Sterility 54: 1039–1044, 1990
Crowley WF. Progesterone antagonism. New England Journal of Medicine 315: 1607–1608, 1986
Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy luteectomy evidence. Obstetrical and Gynaecological Survey 33: 69–81, 1978
Dubois C, Ulmann A, Baulieu EE. Contragestion with late luteal administration of RU 486 (Mifepristone). Fertility and Sterility 50: 593–596, 1988
Editorial. Mifepristone: widening the choice for women. Lancet 2: 1112–1113, 1989
Editorial. A death associated with mifepristone/sulprostone. Lancet 337: 969–970, 1991
Frank PI, McNamee R, Hannaford PC, Kay CR, Hirsch S. The effect of induced abortion on subsequent pregnancy outcome. British Journal of Obstetrics and Gynaecology 98: 1015–1024, 1991
Frydman R, Taylor S, Ulmann A. Transplacental passage of mifepristone. Lancet 2: 1252, 1985
Frydman R, Fernandez H, Pons JC, Ulmann A. Mifepristone (RU486) and therapeutic late pregnancy termination: a double-blind study of two different doses. Human Reproduction 3: 803–806, 1988
Frydman R, Baton C, Lelaidier C, Vial M, Bourget PH, et al. Mifepristone for induction of labour. Lancet 337: 488–489, 1991
Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Postcoital contraception with mifepristone. Lancet 337: 1414–1415, 1991
Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. Journal of Neurosurgery 74: 861–866, 1991
Gupta JK, Johnson N. Effect of mifepristone on dilation of the pregnant and nonpregnant cervix. Lancet 335: 1238–1240, 1990
Halbreich U. Treatment of premenstrual syndromes with progesterone antagonists (eg RU 486): political and methodological issues. Psychiatry 53: 407–409, 1990
Hardy RP, New DAT. Effects of the anti-progestin RU 38486 on rat embryos growing in culture. Food and Chemical Toxicology 29: 361–362, 1991
Heard M, Guillebaud J. Medical abortion. British Medical Journal 304: 195–196, 1992
Hempel S. No easy option. Nursing Times 87: 20–21, 1991
Henshaw RC, Templeton AA. Pre-operative cervical preparation before first trimester vacuum aspiration: a randomised controlled comparison between gemeprost and mifepristone (RU 436). British Journal of Obstetrics and Gynaecology 98: 1025–1030, 1991
Henshaw RC, Templeton AA, Naji SA, Russell IT. Medical abortion. Correspondence. British Medical Journal 304: 914, 1992
Hill NCW, Ferguson J, MacKenzie IZ. The efficacy of oral Mifepristone (RU 38,486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability. American Journal of Obstetrics and Gynecology 162: 414–417, 1990
Hull MGR, Gordon C, Beard RW. The organisation and results of a pregnancy termination service in a national health service hospital. The Journal of Obstetrics and Gynaecology of the British Commonwealth 81: 577–587, 1974
Joint Study of the Royal College of General Practitioners and the Royal College of Obstetricians and Gynaecologists. Induced abortion operations and their early sequelae. Journal of the Royal College of General Practitioners 35: 175–180, 1985
Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, et al. Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertility and Sterility 56: 402–407, 1991
Klijn JG, de Jong FH, Bakker GH, Lamberts SW, Rodenburg CJ, et al. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Research 49: 2851–2856, 1989
Kovacs L. Future direction of abortion technology. In Bygdeman M (Ed.) Medical induction of abortion. Bailliere’s Clinical Obstetrics and Gynaecology, Vol. 4, 407–414, Balliere Tindall, London, 1990
Lim BH, Lees, DAR, Bjornsson S, Lunan CB, Cohn MR, et al. Normal development after exposure to mifepristone in early pregnancy. Lancet 336: 257–258, 1990
Loraine JA. Abortion: world perspectives in the mid-1980s. Family Practice 3: 266–271. 1986
Luukkainen T, Heinkinheimo O, Haukkamaa M, Lahteenmaki P. Inhibition of folliculogenesis and ovulation by the antiprogsterone RU 486. Fertility and Sterility 49: 961–963, 1988
Mahler H. The safe motherhood initiative: a call to action. Lancet: 668-670, 1987
Munday D, Francome C, Savage W. Twenty one years of legal abortion. British Medical Journal 298: 1231–1234, 1989
Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, et al. Successful treatment of Cushing’s Syndrome with the glucorticoid antagonist RU 486. Journal of Clinical Endocrinology and Metabolism 61: 536–540, 1985
Obel EB. Fertility following legally induced abortion. Acta Obstetrica Gynecologia Scandanavia 58: 539–542, 1979
Pons JC, Imbert MC, Elefant E, Roux C, Herschkorn P, et al. Development after exposure to mifepristone in early pregnancy. Lancet 338: 763, 1991
Report on Confidential Enquiries into Maternal Deaths in the UK 1985–1987. HMSO, London 1991
Rodger MW, Baird DT. Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. British Journal of Obstetrics and Gynaecology 97: 41–45, 1990
Schulz KF, Grimes DA, Cates W. Measures to prevent cervical injury during suction curettage abortion. Lancet 1: 1182–1185, 1983
Silvestre L, Dubois C, Renault M, Rezvani Y, Baulieu EE, et al. Voluntary interruption of pregnancy with mifepristone (RU 486) and a prostaglandin analogue. New England Journal of Medicine 322: 645–648, 1990
Stuenkel CA, Garzo VG, Morris S, Liu JH, Yen SS. Effects of the antiprogesterone RU 486 in the early follicular phase of the menstrual cycle. Fertility and Sterility 53: 642–646, 1990
Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. British Journal of Obstetrics and Gynaecology 95: 126–134, 1988
UK Multicentre Trial. The efficacy and tolerence of mifepristone and prostaglandin in first trimester termination of pregnancy. British Journal of Obstetrics and Gynaecology 97: 480–486, 1990
Urquhart DR, Templeton AA. Psychiatric morbidity and acceptability following medical and surgical methods of induced abortion. British Journal of Obstetrics and Gynaecology 98: 396–399, 1991
Urquhart DR, Templeton AA. The use of mifepristone prior to prostaglandin-induced mid-trimester abortion. Human Reproduction 5: 883–886, 1990
Wolf JP, Chillik CF, Dubois C, Ulmann A, Raulieu EE, et al. Tolerence of perinidatory primate embryos to RU 486 exposure in vitro and in vivo. Contraception 41: 85–92, 1990
World Health Organization. Induced abortion. Technical report series, No. 623, World Health Organization, Geneva, 1978
Ylikorkala O, Alfthan H, Kaariainen M, Rapeli T, Lahteenmaki P. Outpatient therapeutic abortion with mifepristone. Obstetrics and Gynecology 74: 653–657, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Henshaw, R.C., Templeton, A.A. Mifepristone. Drugs 44, 531–536 (1992). https://doi.org/10.2165/00003495-199244040-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199244040-00001